Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer
Conclusions: Patients with mCRC treated using regorafenib who experienced severe HFSR showed better overall survival than patients without severe HFSR. Severe HFSR may offer an early surrogate marker for the efficacy of regorafenib in patients with mCRC.Oncology (Source: Oncology)
Source: Oncology - February 14, 2019 Category: Cancer & Oncology Source Type: research

Erratum
Oncology (Source: Oncology)
Source: Oncology - February 8, 2019 Category: Cancer & Oncology Source Type: research

Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment
Cancer therapy decisions are often made according to the histopathological-molecular profile of tumor tissue obtained from surgery or biopsy. It has been shown that tumor profiles change with time and treatment, and that tumor tissue is heterogeneous. Thus, other approaches that are easily accessible and less invasive than surgery or biopsy to monitor responses to treatment and predict relapses are urgently needed. In the last few years, the term “liquid biopsies” has been introduced to represent multifunctional circulating biomarkers in the peripheral blood and other physiological fluids of patients with cance...
Source: Oncology - January 17, 2019 Category: Cancer & Oncology Source Type: research

Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment.
Abstract Cancer therapy decisions are often made according to the histopathological-molecular profile of tumor tissue obtained from surgery or biopsy. It has been shown that tumor profiles change with time and treatment, and that tumor tissue is heterogeneous. Thus, other approaches that are easily accessible and less invasive than surgery or biopsy to monitor responses to treatment and predict relapses are urgently needed. In the last few years, the term "liquid biopsies" has been introduced to represent multifunctional circulating biomarkers in the peripheral blood and other physiological fluids of pat...
Source: Oncology - January 17, 2019 Category: Cancer & Oncology Authors: Eigeliene N, Saarenheimo J, Jekunen A Tags: Oncology Source Type: research

Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy
Conclusion: We conclude that a multidisciplinary therapeutic strategy based on EBRT should be proactively selected in the treatment of advanced HCC with MVI.Oncology (Source: Oncology)
Source: Oncology - January 16, 2019 Category: Cancer & Oncology Source Type: research

Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy.
CONCLUSION: We conclude that a multidisciplinary therapeutic strategy based on EBRT should be proactively selected in the treatment of advanced HCC with MVI. PMID: 30650415 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - January 16, 2019 Category: Cancer & Oncology Authors: Iwamoto H, Nomiyama M, Niizeki T, Shimose S, Shirono T, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Kuromatsu R, Ogo E, Abe T, Tanaka M, Koga H, Torimura T Tags: Oncology Source Type: research

Co-Occurring Symptoms Contribute to Persistent Fatigue in Prostate Cancer
Conclusions: Persistent fatigue at 1 year after EBRT in prostate cancer survivors is likely related to a cluster of symptoms elicited by chronic inflammation. Therapies that target each of these symptoms will likely reduce fatigue in this patient population.Oncology (Source: Oncology)
Source: Oncology - January 13, 2019 Category: Cancer & Oncology Source Type: research

Co-Occurring Symptoms Contribute to Persistent Fatigue in Prostate Cancer.
CONCLUSIONS: Persistent fatigue at 1 year after EBRT in prostate cancer survivors is likely related to a cluster of symptoms elicited by chronic inflammation. Therapies that target each of these symptoms will likely reduce fatigue in this patient population. PMID: 30625479 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - January 9, 2019 Category: Cancer & Oncology Authors: Feng LR, Fuss T, Dickinson K, Ross A, Saligan LN Tags: Oncology Source Type: research

Erratum
Oncology (Source: Oncology)
Source: Oncology - December 19, 2018 Category: Cancer & Oncology Source Type: research

Prelims.
Authors: PMID: 30554194 [PubMed - in process] (Source: Oncology)
Source: Oncology - December 18, 2018 Category: Cancer & Oncology Tags: Oncology Source Type: research

Evolution of the International Sarcoma Community: A Personal Perspective.
PMID: 30554195 [PubMed - in process] (Source: Oncology)
Source: Oncology - December 18, 2018 Category: Cancer & Oncology Authors: Demetri GD Tags: Oncology Source Type: research

Advancing towards Better Cooperation for Better Sarcoma Prognoses.
oto J Abstract Multidisciplinary teams (MDTs) are necessary to deliver the best sarcoma care. Planning the optimal therapeutic strategy per patient requires input and expertise from several disciplines. Case/cohort studies have reported improved patient outcomes associated with treatment by MDTs and/or treatment in sarcoma centres. Many countries have established national networks of sarcoma reference centres and most have developed evidence-based clinical practice guidelines agreed using multidisciplinary expertise. In many countries, sarcoma networks are organised as cooperative groups. These groups are committe...
Source: Oncology - December 18, 2018 Category: Cancer & Oncology Authors: Martín Broto J Tags: Oncology Source Type: research

Making the Best of Available Options for Optimal Sarcoma Treatment.
Abstract For 35 years options for treating advanced soft tissue sarcoma (STS) were limited to doxorubicin, dacarbazine and ifosfamide. In 2007, trabectedin was approved. Since then, several other agents have become available and many more are in development, ushering in a new era in disease management. Considerable scope exists for improving outcomes of advanced STS through better trial design and improved patient care in everyday practice. After anthracycline failure, there are a range of treatment options and, increasingly, the choice of therapy is histology driven. Introduction of newer agents and optimising us...
Source: Oncology - December 18, 2018 Category: Cancer & Oncology Authors: Le Cesne A Tags: Oncology Source Type: research

Prelims
Oncology 2018;95(suppl 1):I –III (Source: Oncology)
Source: Oncology - December 14, 2018 Category: Cancer & Oncology Source Type: research

Evolution of the International Sarcoma Community: A Personal Perspective
Oncology 2018;95(suppl 1):1 –4 (Source: Oncology)
Source: Oncology - December 14, 2018 Category: Cancer & Oncology Source Type: research

Advancing towards Better Cooperation for Better Sarcoma Prognoses
Multidisciplinary teams (MDTs) are necessary to deliver the best sarcoma care. Planning the optimal therapeutic strategy per patient requires input and expertise from several disciplines. Case/cohort studies have reported improved patient outcomes associated with treatment by MDTs and/or treatment in sarcoma centres. Many countries have established national networks of sarcoma reference centres and most have developed evidence-based clinical practice guidelines agreed using multidisciplinary expertise. In many countries, sarcoma networks are organised as cooperative groups. These groups are committed to delivering continui...
Source: Oncology - December 14, 2018 Category: Cancer & Oncology Source Type: research

Making the Best of Available Options for Optimal Sarcoma Treatment
For 35 years options for treating advanced soft tissue sarcoma (STS) were limited to doxorubicin, dacarbazine and ifosfamide. In 2007, trabectedin was approved. Since then, several other agents have become available and many more are in development, ushering in a new era in disease management. Considerable scope exists for improving outcomes of advanced STS through better trial design and improved patient care in everyday practice. After anthracycline failure, there are a range of treatment options and, increasingly, the choice of therapy is histology driven. Introduction of newer agents and optimising use of established a...
Source: Oncology - December 14, 2018 Category: Cancer & Oncology Source Type: research

Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival
Conclusions: High miR-93 and miR-200a levels in cancer cells of PDAC were associated with better differentiation, and miR-200a expression in benign tissue with excellent RFS. Keap1 and Nrf2 mRNA levels showed prominent down-regulation in cancerous versus benign tissue, but they were not associated with disease aggressiveness or outcome.Oncology (Source: Oncology)
Source: Oncology - December 13, 2018 Category: Cancer & Oncology Source Type: research

CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer
Conclusion: Our results revealed that the presence of CIMP independently predicts poor OS in patients with stage IV CRC.Oncology (Source: Oncology)
Source: Oncology - December 13, 2018 Category: Cancer & Oncology Source Type: research

Electronic Patient-Reported Outcomes: A New Standard of Care?
Oncology (Source: Oncology)
Source: Oncology - December 13, 2018 Category: Cancer & Oncology Source Type: research

Electronic Patient-Reported Outcomes: A New Standard of Care?
PMID: 30540993 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - December 12, 2018 Category: Cancer & Oncology Authors: Putora PM Tags: Oncology Source Type: research

CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer.
CONCLUSION: Our results revealed that the presence of CIMP independently predicts poor OS in patients with stage IV CRC. PMID: 30540994 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - December 12, 2018 Category: Cancer & Oncology Authors: Chen KH, Lin LI, Tseng LH, Lin YL, Liau JY, Tsai JH, Liang JT, Lin BR, Cheng AL, Yeh KH Tags: Oncology Source Type: research

Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival.
CONCLUSIONS: High miR-93 and miR-200a levels in cancer cells of PDAC were associated with better differentiation, and miR-200a expression in benign tissue with excellent RFS. Keap1 and Nrf2 mRNA levels showed prominent down-regulation in cancerous versus benign tissue, but they were not associated with disease aggressiveness or outcome. PMID: 30537722 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - December 11, 2018 Category: Cancer & Oncology Authors: Karihtala P, Porvari K, Soini Y, Eskelinen M, Juvonen P, Haapasaari KM Tags: Oncology Source Type: research

Digital Follow-Up and the Perspective of Patient-Centered Care in Oncology: What ’s the PROblem?
There is accumulating evidence from randomized trials suggesting that digital patient-centered care allows a more reliable detection of tumour-related symptoms and adverse events – with a direct impact on overall survival. Consequently, a variety of unsynchronized approaches were kicked off to (electronically) measure patient-reported outcomes (PROs). Despite increasing evidence that PRO data are highly relevant for patient care, the data generated in these initial project s lack standardized processing pathways in order to impact clinical routine; therefore, potential future routine PRO assessments require adequate ...
Source: Oncology - December 5, 2018 Category: Cancer & Oncology Source Type: research

Digital Follow-Up and the Perspective of Patient-Centered Care in Oncology: What's the PROblem?
Abstract There is accumulating evidence from randomized trials suggesting that digital patient-centered care allows a more reliable detection of tumour-related symptoms and adverse events - with a direct impact on overall survival. Consequently, a variety of unsynchronized approaches were kicked off to (electronically) measure patient-reported outcomes (PROs). Despite increasing evidence that PRO data are highly relevant for patient care, the data generated in these initial projects lack standardized processing pathways in order to impact clinical routine; therefore, potential future routine PRO assessments requir...
Source: Oncology - December 5, 2018 Category: Cancer & Oncology Authors: Giordano FA, Welzel G, Siefert V, Jahnke L, Ganslandt T, Wenz F, Grosu AL, Heinemann F, Nicolay NH Tags: Oncology Source Type: research

Acknowledgement to the Reviewers
Oncology 2018;95:381 –382 (Source: Oncology)
Source: Oncology - November 30, 2018 Category: Cancer & Oncology Source Type: research

Contents Vol. 95, 2018
Oncology 2018;95:I –VI (Source: Oncology)
Source: Oncology - November 30, 2018 Category: Cancer & Oncology Source Type: research

Molecular Epidemiology of < b > < i > ALK < /i > < /b > Rearrangements in Advanced Lung Adenocarcinoma in Latin America
Conclusions: Although there is a clear country and continental variability in terms ofALKr frequency, this difference is not significant and the overall incidence ofALKr in Latin America does not differ from the rest of the world.Oncology (Source: Oncology)
Source: Oncology - November 26, 2018 Category: Cancer & Oncology Source Type: research

Molecular Epidemiology of ALK Rearrangements in Advanced Lung Adenocarcinoma in Latin America.
CONCLUSIONS: Although there is a clear country and continental variability in terms of ALKr frequency, this difference is not significant and the overall incidence of ALKr in Latin America does not differ from the rest of the world. PMID: 30476928 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - November 26, 2018 Category: Cancer & Oncology Authors: Arrieta O, Cardona AF, Bramuglia G, Cruz-Rico G, Corrales L, Martín C, Imaz-Olguín V, Castillo O, Cuello M, Rojas-Bilbao É, Casas G, Fernández C, Arén Frontera O, Denninghoff V, Recondo G, Avilés-Salas A, Mas-Lopez LA, Oblitas G, Rojas L, Piottante Tags: Oncology Source Type: research

Machine Learning and Imaging Informatics in Oncology
In the era of personalized and precision medicine, informatics technologies utilizing machine learning (ML) and quantitative imaging are witnessing a rapidly increasing role in medicine in general and in oncology in particular. This expanding role ranges from computer-aided diagnosis to decision support of treatments with the potential to transform the current landscape of cancer management. In this review, we aim to provide an overview of ML methodologies and imaging informatics techniques and their recent application in modern oncology. We will review example applications of ML in oncology from the literature, identify c...
Source: Oncology - November 23, 2018 Category: Cancer & Oncology Source Type: research

Machine Learning and Imaging Informatics in Oncology.
Abstract In the era of personalized and precision medicine, informatics technologies utilizing machine learning (ML) and quantitative imaging are witnessing a rapidly increasing role in medicine in general and in oncology in particular. This expanding role ranges from computer-aided diagnosis to decision support of treatments with the potential to transform the current landscape of cancer management. In this review, we aim to provide an overview of ML methodologies and imaging informatics techniques and their recent application in modern oncology. We will review example applications of ML in oncology from the lite...
Source: Oncology - November 23, 2018 Category: Cancer & Oncology Authors: Tseng HH, Wei L, Cui S, Luo Y, Ten Haken RK, El Naqa I Tags: Oncology Source Type: research

Modern Information Technology for Cancer Research: What ’s in IT for Me? An Overview of Technologies and Approaches
Information technology (IT) can enhance or change many scenarios in cancer research for the better. In this paper, we introduce several examples, starting with clinical data reuse and collaboration including data sharing in research networks. Key challenges are semantic interoperability and data access (including data privacy). We deal with gathering and analyzing genomic information, where cloud computing, uncertainties and reproducibility challenge researchers. Also, new sources for additional phenotypical data are shown in patient-reported outcome and machine learning in imaging. Last, we focus on therapy assistance, in...
Source: Oncology - November 15, 2018 Category: Cancer & Oncology Source Type: research

Quantitative RT-PCR Assay for Detecting Lymph Node Metastasis in Endometrial Cancer: A Preliminary Study
Conclusions: Our results demonstrated that qRT-PCR assay, usingCK19 mRNA, exhibits a high accuracy for detecting LN metastasis in EC and represents a useful alternative to conventional pathological diagnosis of EC.Oncology (Source: Oncology)
Source: Oncology - November 15, 2018 Category: Cancer & Oncology Source Type: research

Modern Information Technology for Cancer Research: What's in IT for Me? An Overview of Technologies and Approaches.
t F Abstract Information technology (IT) can enhance or change many scenarios in cancer research for the better. In this paper, we introduce several examples, starting with clinical data reuse and collaboration including data sharing in research networks. Key challenges are semantic interoperability and data access (including data privacy). We deal with gathering and analyzing genomic information, where cloud computing, uncertainties and reproducibility challenge researchers. Also, new sources for additional phenotypical data are shown in patient-reported outcome and machine learning in imaging. Last, we focus on ...
Source: Oncology - November 15, 2018 Category: Cancer & Oncology Authors: Ahlbrandt J, Lablans M, Glocker K, Stahl-Toyota S, Maier-Hein K, Maier-Hein L, Ückert F Tags: Oncology Source Type: research

Quantitative RT-PCR Assay for Detecting Lymph Node Metastasis in Endometrial Cancer: A Preliminary Study.
Abstract OBJECTIVE: The detection accuracy of sentinel lymph node (SLN) metastasis by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) for endometrial cancer (EC) remains unclear and was assessed in this preliminary study. METHODS: We studied primary cancer tissues and pelvic lymph nodes (PLN) from 105 patients with EC. qRT-PCR assay was performed to determine the copy numbers of CK19 mRNA in EC tissues, and negative and positive LN samples. Further, qRT-PCR results were compared with pathological findings. RESULTS: CK19 mRNA expression was detected in 98% (104/106) of the tumors, w...
Source: Oncology - November 14, 2018 Category: Cancer & Oncology Authors: Togami S, Kawamura T, Fukuda M, Yanazume S, Kamio M, Kobayashi H Tags: Oncology Source Type: research

A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of < b > < i > BCOR < /i > < /b >
Conclusion:BCOR-ITDs define a rare subset of pediatric sarcomas and clinically aggressive endometrial stromal sarcoma cases, as defined by NGS for the first time. Our findings help delineate the pan-cancer landscape of this alteration and suggest the need for focused investigation to delineate the pro-oncogenic function ofBCOR, along with any sensitivity to targeted therapies.Oncology (Source: Oncology)
Source: Oncology - October 31, 2018 Category: Cancer & Oncology Source Type: research

Erratum
Oncology 2018;95:1 (Source: Oncology)
Source: Oncology - October 31, 2018 Category: Cancer & Oncology Source Type: research

Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients
Conclusion: The results of the current study suggest that patients whose PD-1 therapy has been discontinued in response can have a long IO therapy-free period without need for a next line of therapy.Oncology (Source: Oncology)
Source: Oncology - October 31, 2018 Category: Cancer & Oncology Source Type: research

A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCOR.
CONCLUSION: BCOR-ITDs define a rare subset of pediatric sarcomas and clinically aggressive endometrial stromal sarcoma cases, as defined by NGS for the first time. Our findings help delineate the pan-cancer landscape of this alteration and suggest the need for focused investigation to delineate the pro-oncogenic function of BCOR, along with any sensitivity to targeted therapies. PMID: 30380541 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - October 31, 2018 Category: Cancer & Oncology Authors: Juckett LT, Lin DI, Madison R, Ross JS, Schrock AB, Ali S Tags: Oncology Source Type: research

Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients.
CONCLUSION: The results of the current study suggest that patients whose PD-1 therapy has been discontinued in response can have a long IO therapy-free period without need for a next line of therapy. PMID: 30380551 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - October 31, 2018 Category: Cancer & Oncology Authors: Iivanainen S, Koivunen JP Tags: Oncology Source Type: research

Mountains and Chasms: Surveying the Oncogenomic Publication Landscape
Cancers arise from the accumulation of somatic genome mutations, with varying contributions of intrinsic (i.e., genetic predisposition) and extrinsic (i.e., environmental) factors. For the understanding of malignant clones, precise information about their genomic composition has to be correlated with morphological, clinical, and individual features in the context of the available medical knowledge. Rapid improvements in molecular profiling techniques, the accumulation of a large amount of data in genomic alterations in human malignancies, and the expansion of bioinformatic tools and methodologies have facilitated the under...
Source: Oncology - October 26, 2018 Category: Cancer & Oncology Source Type: research

Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer
Conclusion: As a second-line chemotherapy for unresectable pancreatic cancer, although the efficacy in both groups was comparable and we can expect fewer toxicities with alternate-day administration of S-1, the noninferiority of alternate-day treatment to daily treatment with S-1 was not verified.Oncology (Source: Oncology)
Source: Oncology - October 26, 2018 Category: Cancer & Oncology Source Type: research

Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer
Conclusions: Patients with advanced gastric cancer with performance status 2, hemoglobin #x3c; 10 g/dL, and NLR before first-line chemotherapy ≥3 are not likely to benefit from second-line chemotherapy.Oncology (Source: Oncology)
Source: Oncology - October 26, 2018 Category: Cancer & Oncology Source Type: research

Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program
Conclusions: Our data indicated that nintedanib-docetaxel combination could be considered to be effective treatment in EGFR TKI-resistant EGFR mutant NSCLC.Oncology (Source: Oncology)
Source: Oncology - October 26, 2018 Category: Cancer & Oncology Source Type: research

Impact of Epidermal Growth Factor Receptor Mutation on Clinical Outcomes of Nintedanib Plus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer from the Korean Named Patient Program.
CONCLUSIONS: Our data indicated that nintedanib-docetaxel combination could be considered to be effective treatment in EGFR TKI-resistant EGFR mutant NSCLC. PMID: 30368503 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - October 26, 2018 Category: Cancer & Oncology Authors: Hong SH, An HJ, Kim K, Lee SS, Lee YG, Yuh YJ, Park IC, Chae YS, Jang TW, Kang JH Tags: Oncology Source Type: research

Mountains and Chasms: Surveying the Oncogenomic Publication Landscape.
Abstract Cancers arise from the accumulation of somatic genome mutations, with varying contributions of intrinsic (i.e., genetic predisposition) and extrinsic (i.e., environmental) factors. For the understanding of malignant clones, precise information about their genomic composition has to be correlated with morphological, clinical, and individual features in the context of the available medical knowledge. Rapid improvements in molecular profiling techniques, the accumulation of a large amount of data in genomic alterations in human malignancies, and the expansion of bioinformatic tools and methodologies have fac...
Source: Oncology - October 26, 2018 Category: Cancer & Oncology Authors: Carrio-Cordo P, Baudis M Tags: Oncology Source Type: research

Randomized Phase II Study of Consecutive-Day versus Alternate-Day Treatment with S-1 as Second-Line Chemotherapy in Advanced Pancreatic Cancer.
CONCLUSION: As a second-line chemotherapy for unresectable pancreatic cancer, although the efficacy in both groups was comparable and we can expect fewer toxicities with alternate-day administration of S-1, the noninferiority of alternate-day treatment to daily treatment with S-1 was not verified. PMID: 30368509 [PubMed - as supplied by publisher] (Source: Oncology)
Source: Oncology - October 26, 2018 Category: Cancer & Oncology Authors: Ishikawa T, Kawashima H, Ohno E, Matsubara H, Sasaki Y, Achiwa K, Kanamori A, Sumi H, Hirai T, Nonogaki K, Tsuzuki T, Kuroiwa M, Hattori M, Maruta S, Hiramatsu T, Ando M, Hashimoto S, Hirooka Y Tags: Oncology Source Type: research

Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer.
Abstract OBJECTIVES: The neutrophil-to-lymphocyte ratio (NLR) has been proposed as an indicator of cancer-related inflammation. The aim of our study was to examine the prognostic value of the NLR for patients with advanced gastric cancer receiving second-line chemotherapy. METHODS: The association of overall survival (OS) in second-line chemotherapy and the clinicopathological findings including NLR were analyzed retrospectively. The selection criteria were patients who received second-line chemotherapy between January 2010 and June 2015, had histologically confirmed gastric adenocarcinoma, and were followed ...
Source: Oncology - October 26, 2018 Category: Cancer & Oncology Authors: Inoue D, Sekiguchi S, Yamagata W, Maeda G, Yamada D, Fujiwara S, Itou S, Kurihara M, Hijioka Y, Shimoji K, Fujiki J, Nakazono A, Horike H, Yoshioka A, Ogura Y, Hatao F, Imamura K, Namiki S Tags: Oncology Source Type: research

Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months
Conclusion: Pmab showed more favorable outcomes in patients treated with bevacizumab within the last 6 months. The interval between prior bevacizumab and subsequent anti-EGFR therapy may be useful for determining the optimal anti-EGFR therapy.Oncology (Source: Oncology)
Source: Oncology - October 25, 2018 Category: Cancer & Oncology Source Type: research

Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months.
This study aimed to compare Pmab and Cmab according to the interval between bevacizumab discontinuation and anti-EGFR antibody initiation (bevacizumab-free interval; BFI). METHODS: We retrospectively evaluated mCRC patients who received Cmab or Pmab in combination with irinotecan at two institutions. Inclusion criteria were histologically confirmed mCRC, with KRAS exon 2 wild-type tumor, refractory or intolerant to fluoropyrimidines, oxali platin, and irinotecan. RESULTS: One-hundred-seventy-eight patients fulfilled the eligibility criteria. Among them, there was no significant difference in overall survival (OS)...
Source: Oncology - October 25, 2018 Category: Cancer & Oncology Authors: Hayashi K, Mitani S, Taniguchi H, Yasui H, Muro K, Mori K, Gotoda T, Yamazaki K Tags: Oncology Source Type: research